RedDress, a Tel Aviv, Israel-based personalized and autologous wound management solution created from patients own blood, raised $26M in Series D funding.
The round, which brought the total amount to $43M, saw participation from ATHOS Biopharma, and other life science investors including Investors Group of HCS Capital and the Ragnar Crossover Fund.
The company intends to use the funds to support increased adoption of its product suite, establishment of global partnerships, and the expansion of its proprietary blood-based technology.
Led by CEO Alon Kushnir, RedDress is a provider of personalized and autologous wound management solutions created from patients’ own blood. Its suite of ActiGraft products are working to wound care, treating a wide variety of chronic wounds including diabetic and neuropathic ulcers, venous ulcers, pressure injuries, traumatic wounds, post-surgical wounds, skin tears, surgical wounds and more. ActiGraft wound care systems are available in 40 countries across five continents including Brazil, Canada, Hong Kong, India, Mexico, Turkey, United Arab Emirates, South Africa, Ireland, and Italy.
Since RedDress received FDA clearance and a CE Mark in 2020, ActiGraft has helped over 6,000 patients across the spectrum of healthcare facilities in the United States and 30 other countries.
The company has a U.S. subsidiary, RedDress Inc., located in Jacksonville, Florida.
FinSMEs
24/05/2023